0 Members and 1 Guest are viewing this topic.
Quote from: Kempenstein on February 23, 2012, 10:53:13 AM when I hesitated a guess at treatment costing between one and two thousand pounds his response was "something like that yes"!
QuoteSo, my guess is that it will be on the market 12-18 months after March of 2012, which would be March of 2013 - September 2013. All anyone can do is guess.
QuoteIn an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether US drugs behemoth Pfizer's (NYSE: PFE) Xiapex (collagenase extracted from Clostridium histolyticum) offers an added benefit in comparison with conventional regimens for the treatment of Dupuytren's contracture.However, such an added benefit cannot be inferred from the dossier, as the drug manufacturer presented either no data or unsuitable data on the drug, which is approved in Europe for this condition (The Pharma Letter March 31, 2011), the review body concluded.
QuoteBerlin -After Boehringer Ingelheim and Eli Lilly have withdrawn Trajenta (Linagliptin) from the market, Pfizer is taking it's first drug from the market. Starting this wednesday the sales of Xiapex are stopped in Germany because Pfizer refuses to renegociate pricing with the Health Insurance associations.The medication ist taken completely off the german Market. Pfizer has notified wholesalers and pharmacists it is taking back any stocks.
QuoteThere is a lot of $$$ involved in this business
Quotemany men has a string of plaque along the shaft from the top to the base. How many injections is necessary to dissolve all of that? The plaque is only a symptom of an underlying "unknown" condition. Without understanding/removing this underlying condition there will be a recurrences of new plaque
QuoteAuxilium plans to file a supplemental Biologics License Application (sBLA) with the FDA seeking approval for the potential use of XIAFLEX in the treatment of Peyronies Disease by the end of 2012. If approved by the FDA, XIAFLEX is expected to be the first biologic therapy indicated for the treatment of Peyronies Disease.
Quote from: charlie44 on May 31, 2012, 09:14:35 AMI had an appointment with a leading Peyronies Uro yesterday. He was involved in the FDA Xiaflex trials.He said the FDA will open the data on June 23rd, and then they have 6-12 months to approve. He thinks it might get approved on the quick side (six months) as it is the only medicine specifically being identified to treat Peyronies. So end of 2012 at best, mid 2013 at worst.
QuoteAuxilium plans to file a supplemental Biologics License Application (sBLA) with the FDA seeking approval for the potential use of XIAFLEX in the treatment of Peyronies Disease by the end of 2012.